Pyrrylphenylethanones Related to Cathinone and Lefetamine: Synthesis and Pharmacological Activities')

Total Page:16

File Type:pdf, Size:1020Kb

Pyrrylphenylethanones Related to Cathinone and Lefetamine: Synthesis and Pharmacological Activities') PyrrylphenylethanonesRelated to Cathinone and Lefetamine 403 Pyrrylphenylethanones Related to Cathinone and Lefetamine: Synthesis and Pharmacological Activities') Silvio Massa")', Roberto Di Santo", Antonello Main),Marino Artico"),Gian Car10 Pantaleonib),Raffaele Giorgib),and Maria Francesca Coppolinob) a) Dipartimento di Studi farmaceutici, Universita di Rma"La Sapienza", P. le Aldo Moro 5,1-00185 Roma (Italy) b, Caedra di Farmacologia medica, Universita di I'Aquila, Via S. Sisto 12.1-67100 1'Aquila (Italy) Received April 30,1991 The synthesis of various pynylphenylethanones resembling cathinone and Mit Cathinon und Lefetamin verwandte Pyrrylphenylethanone: Synthe- lefetamine is described starting from 2-chlon+l-(l-rnethyl-lH-pyrrol-2-yl~ se und pharmakologische Wirkungen 2-phenylethan-l-one. Some derivatives showed good antinociceptic activity, Die Synthese der Titelve&indungen, ausgehend von 2-CNor-l-(l-methyl- c.dle to that of morphine. The neuropsychopharmacological of IH-ppl-2-yl)-2-phenylethan-l -on, wird beschrieben. dieser Deri- title compounds has been atso studied to explore hiraction on C.N.S. Einige vate zeigen gute antinociceptive Eigenschaften, vergleichbar mit denen des Morphins. Das neumpsychophmnakologischeProf3 der Titelverbindungen wurde untersucht, um entspr. ZNS-Wiricungen zu studieren Research on simpler analogues of morphine 1 led to the discovery of These interesting data led us to synthesize various sub- lefetamine 2, a potent drug used as analgesic in clinical practice'). stituted aminopyrrylphenylethanones6 as an attempt to ac- Lefetamine belongs to the class of phenethylamines which include quire new potential analgesic agents. among others amphetamine 3 and two natural products, cathine (4) and This work is a part of our running program on lefetamine derivatives cathinone (3,found in khat exmts. Due to their shucaual similarity with bearing a pple moiety, one of which, N,N-dimethyl-l-pheny1-2-(W- amphetamine, the khatamines are miming the pharmacological profile of pyrrol-l-yl)ethylamine (7), showed analgesic effects comparable to those amphetamine producing similar central and peripheral effects. In particular of lefetamine, but devoid of its neurotoxic effects4)(Scheme I). cathinone (3,the major component of khat, increases the reaction time in All new derivatives here reported have been subjected to the hot-plate and in the writhing tests. Amphetamine also has analgesic phaxmacological screening for analgesic activity and neuro- effects as shown in various experimental psychopharmacological effects. We tested also our com- pounds in vivo in the phenylquinone-induced writhing assay for evaluating their interaction with central a2-receptors. Chemistry Friedel-Crafs aroylation of 1-methyl- lH-pyrrole with a- chlorophenacetyl chloride/AlC13 afforded the expected 2- 1 2 and 3-substituted pyrrylketones 8 and 9 (Scheme 2)? Reaction of 2-chloro-1-( l-methyl-lH-pyrro1-2-yl)-2-phe nylethan- 1-one (8) with potassium phthalimide furnished the phthalimidoketone 10, which led to 2-amino-1-( 1-me- thyl- lH-pyrro1-2-yl)-2-phenylethan-1-one 11 on treatment with hydrazine hydrate (Scheme 3). 3 4 5 _3AICI3 / x+Q&/ N/ N H3C' \ CH.. N/C"3 3 8, 8 9 Scheme 2 6 7 Compound 8 was also reacted with various amines to give Weme 1 aminoketones 12,13, and 14 (Scheme 4). Arch. Pharm. (Weitilwim) 325,403409 (1992) OVCH VerlilgsgesellschaftmbH, D-6940 Weinheim, 1992 0365-6233/92/0707-03 $3.50 + .25/0 404 Artico and coworkers In an attempt to prepare the aminoderivative 11 by reduc- 0 tive cleavage of the corresponding azide6’, we reacted chlo- + KNyJ-a roketone 8 with NaN3 (Scheme 5). However, the expected azido-derivative 16 was not formed, the only product isu- 0 lated being the diketone 15, probably formed by loss of N2 and ammonia. The structure of 15 has been confirmed by n JR-, NMR-, and GC-MS-spectra. Pharmacological Evaluation Derivatives 10-14 were pharmacologically tested in mice in order to explore their neuropsychopharmacological ef- fects (Table l), their antinociceptic activity (Table 2). and their interaction with central a2-receptors (Table 3). Scheme 3 10 11 Neuropsychopharmucological Effects All test derivatives, with the exception of compounds 10, 12b, 13c, and 14, decreased spontaneous motor activity in mice without affecting other neuropsychobehavioural acti- vities. Derivatives 11,12a, and 13f exhibited the highest sig- H3C’ H3C’ nificance (p < 0.001) like morphine. On the contrary, amphe- tamine increased strongly the spontaneous motor activity. 8 12 A significant decrease of the exploratory activity on the hole-board test was observed in the subsequent order mor- phine and amphetamine > 12b and 13c > 14. With our substances animals behaved as disinterested rather than se- date, with an amphetamine-like pharmacological profile. 0M As regards to myorelaxant action all test derivatives were devoid of myorelaxant and ataxic action, with only few ex- ceptions (compound 13g and, at minor extent, compound ci 13d). Significative low effects at the Rota-Rod test (action on motor coordination) were observed with derivatives 13c and 13g. With regard to the anticonvulsant activity, none of test compounds determined any protection from seizures. All compounds showed only a partial protection with particular reference (100% PP) to derivatives 10, 13c, and 13f. This H3C’ behaviour was similar to those of morphine (100% PP) and amphetamine (80% PP). 13 In conclusion, from data on neuropsychobehavioural screening we can observe that all test products did not show any exciting effect at the dose of 20 mg/kg i.p. In general they produced light sedation (decreasing of spontaneous motor activity) without alteration of exploratory activity on the hole-board. These effects can be correlated with a spe- cific antiphobic-anxiolytic activity, which needs to be con- firmed by further pharmacological studies with proper tests. It is interesting to note that these low sedative-anxiolytic effects are not accompanied by myorelaxation and ataxia. Antinociceptive Action. Hot-Plate Test O’W Data of essay on antinociceptic activity (hot-plate test) are H3C’ k H3C’ recorded in Table 2. Two derivatives, 10 and 12d, showed 8 high antinociceptic activity with the same significance (p < 1s Scheme 5 0.001) of both morphine and amphetamine. Good activity, Arch. Pharni. (Weinheim) 325.403409 (1992) F'ynylphenylethanonesRelated to Cathinone and Lefetamine 405 Table 1: Neurobehavioural effects of derivatives 10-14 (dose: 20 m&g ip.)on mice Compd or A8 Bb ?I" C; Dd E= Conlrols k s.Df % f S.D. X f S.D f S.D. x f S.D. 46 :ontrols 164.2106.4 25.627.56 I.2+0.44 106.W31.3 1.6f1.8 40 PP ***g *** 60 NP mphme L40.oL80.37 1 1.ui6.0 1.M1.41 120.M0 1.m1.22 100 PP 00 *** mpheiaminc 548.M29.83 10.4i6.0 I .4i0.54 120.M (40%) 1.21.64 80 PP 20 NP 10 125.2103.Y 24.Xk11.36 2.0 t1.2: 106.W1.3 1 .@I .22 loo PP *.* I1 EO.Of85.9 30.0f5.19 1.2f0.44 110.M22.3 0.4k0.89 40 PP *** 60 NP I2a 259.8k107.3 20.212.75 1.8933 97.6k25.0 7.ok9.87 40 PP ** 60 NP 12b 109.oL105.1 14.2k4.86 I .2+0.44 1 ll.mL67 2.821.48 40 PP 60 NP l2c 336.E91.50 23216.26 1.2M.44 112.E17.8 3.8t3.1 20 PP t 80 NP 12d 355.8kS5.43 27.2t3.56 2.4i2.6 120.E0 1.8i2.4 60 PP ** 40 NP 130 306.8k107.33 17.4fI5.0 1.6a.89 108.M26.83 1B1.73 40 PP *. 60 NP 13b 320.298.31 23.M.27 1.Of0 114.M13.4 O.eO.54 100 NP *(I 13c 406.6i265.3 14.6+5.X5 1.8H1.83 72.6344.8 3.4k1.34 100 PP ** b 13d 311.250.91 23.8M.14 5.w.71 107.6i27.7 3.4i3 .9 20 PP 10 NP 13e 350.6f57.7 I 27.6f5.54 2.0i1.41 120.MO 2.4i1.5 20 PP *** 80 NP 13f 252.6f120.8 .20.Xi4.96 1.8f0.83 116.E8.94 1.452.0 80 PP * * .* * 20 NP 13g 307.4i 153.0 18.M7.0 3.4i1.8 11625.21 4.22.38 20 PP 80 NP 14 378.6k244.7 15.211.34 i.4in.54 99.229.7 2.6f2.79 100 NI a Spontaneous motor activity in the open field (total number of movements in 5 min). bExploratory activity on the hole-board (total number of holes in 5 min). Myorelaxant action (traction tesr time in sec on the horizontal wire for fore-legs). ''Myorelaxant action (traction test how long the animals stayed on wire). * Motor coordination at Rota-Rod (total number of falls in 3 min). Maximal electroshock seizures: PP = % of survival of animals with seizures (partially protected); NP = % of deaths of animals with seizures (non-protec- ted). Average f standard deviation. Significance: (*) or (") 0.05 > p > 0.Q (**) or ("") 0.02 > p > 0.001; (.I*)or (On') p < 0.001. although with minor significance, was exerted by deriva- 10 is active, showing the best significance. The antinocicep tives 12a (0.02 > p > 0.01) and 11 (0.05 > p > 0.02). All tic activity was also retained significantly by the N-mono- other test derivatives did not show statistically significant substituted derivative 12d. The interesting pharmacological activity at the hot-plate test. profile of phthalimidoderivative 10 encourages further re- Derivatives 11, 12% and 12d exhibit some sedative ef- search on the synthesis and pharmacological screening of fects, whereas derivative 10 is devoid of any effects on the mono- and disubstituted amides of 11 in order to obtain new behavioural profile. For the latter compound positive effects analgesic agents of potential clinical usefulness.
Recommended publications
  • FSI-D-16-00226R1 Title
    Elsevier Editorial System(tm) for Forensic Science International Manuscript Draft Manuscript Number: FSI-D-16-00226R1 Title: An overview of Emerging and New Psychoactive Substances in the United Kingdom Article Type: Review Article Keywords: New Psychoactive Substances Psychostimulants Lefetamine Hallucinogens LSD Derivatives Benzodiazepines Corresponding Author: Prof. Simon Gibbons, Corresponding Author's Institution: UCL School of Pharmacy First Author: Simon Gibbons Order of Authors: Simon Gibbons; Shruti Beharry Abstract: The purpose of this review is to identify emerging or new psychoactive substances (NPS) by undertaking an online survey of the UK NPS market and to gather any data from online drug fora and published literature. Drugs from four main classes of NPS were identified: psychostimulants, dissociative anaesthetics, hallucinogens (phenylalkylamine-based and lysergamide-based materials) and finally benzodiazepines. For inclusion in the review the 'user reviews' on drugs fora were selected based on whether or not the particular NPS of interest was used alone or in combination. NPS that were use alone were considered. Each of the classes contained drugs that are modelled on existing illegal materials and are now covered by the UK New Psychoactive Substances Bill in 2016. Suggested Reviewers: Title Page (with authors and addresses) An overview of Emerging and New Psychoactive Substances in the United Kingdom Shruti Beharry and Simon Gibbons1 Research Department of Pharmaceutical and Biological Chemistry UCL School of Pharmacy
    [Show full text]
  • Title 21 Food and Drugs Part 1300 to End
    Title 21 Food and Drugs Part 1300 to End Revised as of April 1, 2011 Containing a codification of documents of general applicability and future effect As of April 1, 2011 Published by the Office of the Federal Register National Archives and Records Administration as a Special Edition of the Federal Register VerDate Mar<15>2010 07:57 May 04, 2011 Jkt 223073 PO 00000 Frm 00001 Fmt 8091 Sfmt 8091 Y:\SGML\223073.XXX 223073 erowe on DSK5CLS3C1PROD with CFR U.S. GOVERNMENT OFFICIAL EDITION NOTICE Legal Status and Use of Seals and Logos The seal of the National Archives and Records Administration (NARA) authenticates the Code of Federal Regulations (CFR) as the official codification of Federal regulations established under the Federal Register Act. Under the provisions of 44 U.S.C. 1507, the contents of the CFR, a special edition of the Federal Register, shall be judicially noticed. The CFR is prima facie evidence of the origi- nal documents published in the Federal Register (44 U.S.C. 1510). It is prohibited to use NARA’s official seal and the stylized Code of Federal Regulations logo on any republication of this material without the express, written permission of the Archivist of the United States or the Archivist’s designee. Any person using NARA’s official seals and logos in a manner inconsistent with the provisions of 36 CFR part 1200 is subject to the penalties specified in 18 U.S.C. 506, 701, and 1017. Use of ISBN Prefix This is the Official U.S. Government edition of this publication and is herein identified to certify its authenticity.
    [Show full text]
  • Poisons and Narcotic Drugs (Amendment) Ordinance 1988
    AUSTRALIAN CAPITAL TERRITORY Poisons and Narcotic Drugs (Amendment) Ordinance 1988 No. 96 of 1988 I, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Ordinance under the Seat of Government (Administration) Act 1910. Dated 15 December 1988 N. M. STEPHEN Governor-General By His Excellency’s Command, CLYDE HOLDING Minister of State for the Arts and Territories An Ordinance to amend the Poisons and Narcotic Drugs Ordinance 1978 Short title 1. This Ordinance may be cited as the Poisons and Narcotic Drugs (Amendment) Ordinance 1988.1 Commencement 2. This Ordinance commences on such date as is fixed by the Minister by notice in the Gazette. Principal Ordinance 3. In this Ordinance, “Principal Ordinance” means the Poisons and Narcotic Drugs Ordinance 1978.2 (Ord. 79/88)—Cat. No. Authorised by the ACT Parliamentary Counsel—also accessible at www.legislation.act.gov.au 2 Poisons and Narcotic Drugs (Amendment) No. 96, 1988 Substances to which Division applies 4. Section 27B of the Principal Ordinance is amended by adding at the end the following paragraphs: “; (f) follicle stimulating hormone; (g) luteinising hormone; (h) thalidomide.”. Grant of authorisation 5. Section 27E of the Principal Ordinance is amended— (a) by omitting from paragraph (1) (a) “or cyclofenil” and substituting “, cyclofenil, follicle stimulating hormone or luteinising hormone”; (b) by omitting from paragraph (1) (b) “and”; and (c) by adding at the end of subsection (1) the following word and paragraph: “; and (d) in the case of an application that relates to thalidomide— the applicant is a specialist physician with no less than 5 years’ experience in the treatment of erythema nodosum leprosum.”.
    [Show full text]
  • Acute Toxicity Associated with the Recreational Use of the Novel Dissociative Psychoactive Substance Methoxphenidine
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2014 Acute toxicity associated with the recreational use of the novel dissociative psychoactive substance methoxphenidine Hofer, K E ; Degrandi, C ; Müller, D M ; Zürrer-Härdi, U ; Wahl, S ; Rauber-Lüthy, C ; Ceschi, A Abstract: INTRODUCTION: Methoxphenidine is a novel dissociative designer drug of the diarylethy- lamine class which shares structural features with phencyclidine (PCP), and is not at present subject to restrictive regulations. There is very limited information about the acute toxicity profile of methoxpheni- dine and the only sources are anonymous internet sites and a 1989 patent of the Searle Company. We report a case of analytically confirmed oral methoxphenidine toxicity. CASE DETAILS: A 53-year-old man was found on the street in a somnolent and confusional state. Observed signs and symptoms such as tachycardia (112 bpm), hypertension (220/125 mmHg), echolalia, confusion, agitation, opisthotonus, nys- tagmus and amnesia were consistent with phencyclidine-induced adverse effects. Temperature (99.1°F (37.3°C)) and peripheral oxygen saturation while breathing room air (99%) were normal. Laboratory analysis revealed an increase of creatine kinase (max 865 U/L), alanine aminotransferase (72 U/L) and gamma-glutamyl transpeptidase (123 U/L). Methoxphenidine was identified by a liquid chromatogra- phy tandem mass spectrometry toxicological screening method using turbulent flow online extraction in plasma and urine samples collected on admission. The clinical course was favourable and signs and symptoms resolved with symptomatic treatment. CONCLUSION: Based on this case report and users’ web reports, and compatible with the chemical structure, methoxphenidine produces effects similar to those of the arylcyclohexylamines, as PCP.
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]
  • Annex 2B Tariff Schedule of the United States See General Notes to Annex 2B for Staging Explanation HTSUS No
    Annex 2B Tariff Schedule of the United States See General Notes to Annex 2B for Staging Explanation HTSUS No. Description Base Rate Staging 0101 Live horses, asses, mules and hinnies: 0101.10.00 -Purebred breeding animals Free E 0101.90 -Other: 0101.90.10 --Horses Free E 0101.90.20 --Asses 6.8% B --Mules and hinnies: 0101.90.30 ---Imported for immediate slaughter Free E 0101.90.40 ---Other 4.5% A 0102 Live bovine animals: 0102.10.00 -Purebred breeding animals Free E 0102.90 -Other: 0102.90.20 --Cows imported specially for dairy purposes Free E 0102.90.40 --Other 1 cent/kg A 0103 Live swine: 0103.10.00 -Purebred breeding animals Free E -Other: 0103.91.00 --Weighing less than 50 kg each Free E 0103.92.00 --Weighing 50 kg or more each Free E 0104 Live sheep and goats: 0104.10.00 -Sheep Free E 0104.20.00 -Goats 68 cents/head A 0105 Live poultry of the following kinds: Chickens, ducks, geese, turkeys and guineas: -Weighing not more than 185 g: 0105.11.00 --Chickens 0.9 cents each A 0105.12.00 --Turkeys 0.9 cents each A 0105.19.00 --Other 0.9 cents each A -Other: 0105.92.00 --Chickens, weighing not more than 2,000 g 2 cents/kg A 0105.93.00 --Chickens, weighing more than 2,000 g 2 cents/kg A 0105.99.00 --Other 2 cents/kg A 0106 Other live animals: -Mammals: 0106.11.00 --Primates Free E 0106.12.00 --Whales, dolphins and porpoises (mammals of the order Cetacea); manatees and dugongs (mammals of the order Sirenia) Free E 0106.19 --Other: 2B-Schedule-1 HTSUS No.
    [Show full text]
  • 1,2-Diphenylethylamine Designer Drugs
    1,2-Diphenylethylamine Designer Drugs Metabolism Studies and Toxicological Analysis Using Gas Chromatography-Mass Spectrometry and Liquid Chromatography-Mass Spectrometry Coupled to Low and High Resolution-Mass Spectrometry Dissertation zur Erlangung des Grades des Doktors der Naturwissenschaften der Naturwissenschaftlich-Technischen Fakultät III - Chemie, Pharmazie, Bio- und Werkstoffwissenschaften der Universität des Saarlandes von Carina Sandra Denise Wink Saarbrücken 2016 Tag des Kolloquiums: 17.06.2016 Dekan: Univ.-Prof. Dr.-Ing. Dirk Bähre Berichterstatter: Univ.-Prof. Dr. rer. nat. Dr. h.c. Hans H. Maurer Univ.-Prof. Dr. rer. nat. Rolf W. Hartmann Vorsitz: Univ.-Prof. Dr. med. Veit Flockerzi Akad. Mitarbeiter: Dr. rer. nat. Josef Zapp Die nachfolgende Arbeit entstand unter der Anleitung von Herrn Professor Dr. Dr. h.c. Hans H. Maurer in der Abteilung Experimentelle und Klinische Toxikologie der Fachrichtung 2.4 Experimentelle und Klinische Pharmakologie und Toxikologie der Universität des Saarlandes in Homburg/Saar von November 2010 bis Oktober 2014. Mein besonderer Dank gilt: Herrn Professor Hans H. Maurer für die Möglichkeit, in seinem Arbeitskreis ein breit gefächertes, vollumfängliches wissenschaftliches Arbeiten zu erlernen. Labor- und Personalverantwortung, analytisches Denken und Durchführen, Diskussion mit ihm, Darstellung der wissenschaftlichen Ergebnisse auf Fachkongressen, all dies prägte und forderte heraus, Herrn Professor Rolf W. Hartmann für die Übernahme des Koreferats, den vor mir gegangenen und länger gebliebenen
    [Show full text]
  • Problems of Drug Dependence 1982 Proceedings of the 44Th Annual Scientific Meeting The
    National Institute Drug Abuse MONOGRAPH SERIES Problems of Drug Dependence 1982 Proceedings of the 44th Annual Scientific Meeting The Committee on Problems of Drug Dependence, Inc. U. S. DEPARTMENT OF HEALTH AND HUMAN SERVICE • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Problems of Drug Dependence, 1982 Proceedings of the 44th Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Editor, Louis S. Harris, Ph.D. NIDA Research Monograph 43 April 1983 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Office of Science 5600 Fishers Lane Rockville, Maryland 20657 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science. The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art confer- ences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. University of Connecticut School of Medicine Farmington, Connecticut Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Rochester, New York Lee Robins, Ph.D. Washington University School of Medicine St. Louis, Missouri NIDA Research Monograph Series William Pollin, M.D.
    [Show full text]
  • Chapter 329 [New] Uniform Controlled Substances Act
    CHAPTER 329 [NEW] UNIFORM CONTROLLED SUBSTANCES ACT Part I. General Provisions Section 329-1 Definitions 329-2 Hawaii advisory commission on drug abuse and controlled substances; number; appointment 329-3 Annual report 329-4 Duties of the commission Part II. Standards and Schedules 329-11 Authority to schedule controlled substances 329-12 Nomenclature 329-13 Schedule I tests 329-14 Schedule I 329-15 Schedule II tests 329-16 Schedule II 329-17 Schedule III Tests 329-18 Schedule III 329-19 Schedule IV tests 329-20 Schedule IV 329-21 Schedule V tests 329-22 Schedule V 329-23 Republishing and distribution of schedules Part III. Regulation of Manufacture, Distribution, Prescription, and Dispensing of Controlled Substances 329-31 Rules 329-31.5 Clinics 329-32 Registration requirements 329-33 Registration 329-34 Revocation and suspension of registration 329-35 Order to show cause 329-36 Records of registrants 329-37 Filing requirements 329-38 Prescriptions 329-39 Labels 329-40 Methadone treatment programs Part IV. Offenses and Penalties 329-41 Prohibited acts B-penalties 329-42 Prohibited acts C-penalties 329-43 Penalties under other laws 329-43.5 Prohibited acts related to drug paraphernalia Amended 0612 1 329-44 Notice of conviction to be sent to licensing board, department of commerce and consumer affairs 329-45 Repealed 329-46 Prohibited acts related to visits to more than one practitioner to obtain controlled substance prescriptions 329-49 Administrative penalties 329-50 Injunctive relief Part V. Enforcement and Administrative Provisions 329-51 Powers of enforcement personnel 329-52 Administrative inspections 329-53 Injunctions 329-54 Cooperative arrangements and confidentiality 329-55 Forfeitures 329-56 Burden of proof; liabilities 329-57 Judicial review 329-58 Education and research 329-59 Controlled substance registration revolving fund; established Part VI.
    [Show full text]
  • Drug Abuse (Prevention and Control) 1990-14
    CHAPTER 131 DRUG ABUSE (PREVENTION AND CONTROL) 1990-14 This Act came into operation on 15th August, 1990 by Proclamation (S.I. 1990 No. 85). Amended by: This Act has not been amended Law Revision Orders The following Law Revision Order or Orders authorized the insertion and removal of pages as the case may be under the Law Revision Act Cap.2 now repealed: 1991 LAWS OF BARBADOS CUMULATIVE EDITION 2008 Printed by the Government Printer, Bay Street, St. Michael, by authority of the Government of Barbados Supplement to Official Gazette No. dated , CHAPTER 131 DRUG ABUSE (PREVENTION AND CONTROL) 1990-14 Arrangement of Sections PART I PRELIMINARY 1. Short title 2. Interpretation CONTROLLED DRUGS 3. Meaning of expression controlled drugs PART II RESTRICTIONS RELATING TO CONTROLLED DRUGS ETC. 4. Importation and exportation of controlled drugs 5. Production and supply of controlled drugs 6. Possession of controlled drugs 7. Handling of controlled drugs 8. Misuse of controlled drugs 9. Possession of pipes, equipment etc. THE LAWS OF BARBADOS Printed by the Government Printer, Bay Street, St. Michael by the authority of the Government of Barbados 4 DRUG ABUSE (PREVENTION AND CONTROL) 10. Acts preparatory to the importation, supply etc. of controlled drugs 11. Cultivation of cannabis and coca plant 12. Authorisation of activities otherwise unlawful under foregoing provisions 13. Occupiers etc. of premises etc. to be punishable for permitting certain activities to take place there PART III CONTROLLED DRUGS IN TRANSIT 14. Controlled drugs in transit 15. Removal licences 16. Tampering with controlled drugs in transit 17. Diversion of controlled drugs PART IV DRUG TRAFFICKING AND RELATED OFFENCES 18.
    [Show full text]
  • Food and Drugs Act 2005
    LAWS OF TRINIDAD AND TOBAGO MINISTRY OF LEGAL AFFAIRS www.legalaffairs.gov.tt FOOD AND DRUGS ACT CHAPTER 30:01 Act 8 of 1960 Amended by 39 of 1968 156/1972 *31 of 1980 16 of 1986 12 of 1987 6 of 1993 16 of 1998 6 of 2005 *See Note on Validation at page 2 Current Authorised Pages Pages Authorised (inclusive) by L.R.O. 1–2 .. 1/2009 3–20 .. 1/2006 21–245 .. 1/2009 L.R.O. 1/2009 UPDATED TO DECEMBER 31ST 2009 LAWS OF TRINIDAD AND TOBAGO MINISTRY OF LEGAL AFFAIRS www.legalaffairs.gov.tt 2 Chap. 30:01 Food and Drugs Index of Subsidiary Legislation Page Food and Drugs Regulations (GN 130/1964) … … … … 25 Official Method Notification (GN 54/1972) … … … … 124 *Approval of New Drugs Notification … … … … … 129 †Withdrawal of Approval of New Drugs Notification (GN 51/1969) … … 200 Fish and Fishery Products Regulations (LN 220/1998)…………201 †This Notification (i.e. 51/1969) has been amended by LNs 99 and 114/1984 which have been omitted. *Note on Approval of New Drugs Notification The list of new drugs set out in the Schedule to this Notification has been consolidated as at 31st December 1977. This list is so voluminous and changes to it so frequent that, especially in view of its very limited use by the general public, it is not practicable to update it annually. The references to the amendments to this list since 31st December 1977 are contained in the Current Consolidated Index of Acts and Subsidiary Legislation. †Note on Withdrawal of Approval of New Drugs Notification For references to the Withdrawal of Approval of New Drugs Notifications subsequent to the year 1969 — See the current Consolidated Index of Acts and Subsidiary Legislation.
    [Show full text]
  • Synthesis, Absolute Configuration and in Vitro Cytotoxicity of Deschloroketamine Enantiomers: Rediscovered and Abused Dissociative Anaesthetic NJC
    Volume 42 Number 24 21 December 2018 Pages 19309–20250 NJC New Journal of Chemistry A journal for new directions in chemistry rsc.li/njc ISSN 1144-0546 PAPER Martin Kuchař, Michal Kohout et al. Synthesis, absolute configuration and in vitro cytotoxicity of deschloroketamine enantiomers: rediscovered and abused dissociative anaesthetic NJC View Article Online PAPER View Journal | View Issue Synthesis, absolute configuration and in vitro cytotoxicity of deschloroketamine enantiomers: Cite this: New J. Chem., 2018, 42,19360 rediscovered and abused dissociative anaesthetic† ab c d e Bronislav Jura´sek, ‡ Frantisˇek Kra´lı´k,‡ Silvie Rimpelova´, Jan Cˇejka, c d ab f Vladimı´r Setnicˇka, Toma´ˇs Ruml, Martin Kucharˇ* and Michal Kohout * In this study, we aim to determine differences in cytotoxicity of racemic deschloroketamine and its enantiomers. The synthesized racemate of this recently rediscovered and abused dissociative anaesthetic was resolved by chiral HPLC and the absolute configuration of the enantiomers was assigned using a combination of circular dichroism methods and single-crystal X-ray. Not only the absolute configuration, but also the most preferred conformers present in the crystal were successfully determined by electron and vibrational circular dichroism supported by ab initio calculations, and confirmed by X-ray. The in vitro cytotoxicity of racemic deschloroketamine and its enantiomers was determined for nine different types of cell lines. Generally, Creative Commons Attribution 3.0 Unported Licence. (S)-deschloroketamine exhibited higher cytotoxicity in the majority of cases. For human embryonic Received 22nd June 2018, kidney cells (HEK 293T), the (S)-enantiomer reached the IC50 below 1 mM concentration and, in Accepted 26th October 2018 consequence, proved to be twice as potent as the (R)-enantiomer.
    [Show full text]